Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Esmolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | NPY1R | P25929 | 1/20 | 0.67 |
| ▸ | NPY2R | P49146 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.65 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esmolol SCHEMBL3606 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL3605 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL6509147 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL41088 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL41086 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL28687772 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL30039548 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL1649927 | 0.97 | ADRB2 (0.95) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL9751334 | 0.96 | ADRB2 (0.93) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 | |
| Esmolol SCHEMBL27879439 | 0.95 | ADRB2 (0.91) | ADRB2ADRB1ADRA1ANR3C1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16207 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629378-B2 | Treatment of infantile hemangioma | ARKAYLI BIOPHARMA INC. (US) | 2026-05-19 | — | — | US | claimed |
| US-20260115166-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PHOTORECEPTOR ROD DEGENERATIONS AND GENERATION OF PHOTORECEPTORS | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| EP-4705765-A2 | BUCCAL CELL DIAGNOSIS OF RISK IN FAMILIAL ARRHYTHMIA SYNDROMES | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4042999-B1 | DRUG ACCOMMODATING DEVICE OF SOLID ORAL FORMULATION, AND ORAL ADMINISTRATION AND DELIVERY APPARATUS COMPRISING SAME | SHANGHAI WD PHARMACEUTICAL CO LTD (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| EP-0279844-A1 | RESOLUTION OF dl-METHYL 3- 4-(2-HYDROXY-3-ISOPROPYLAMINO)PROPOXY]PHENYLPROPIONATE (dl-ESMOLOL)] | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-08-31 | — | — | EP | claimed |
| EP-0278158-A2 | Renin inhibitors containing phenylalanyl-histidine replacements | MERCK & CO. INC. (US) | 1988-08-17 | — | — | EP | claimed |
| EP-0273696-A2 | Renin inhibitors containing histidine replacements | MERCK & CO. INC. (US) | 1988-07-06 | — | — | EP | claimed |
| WO-1988001614-A1 | RESOLUTION OF dl-METHYL 3-[4-(2-HYDROXY-3-ISOPROPYLAMINO)PROPOXY]PHENYLPROPIONATE [(dl-ESMOLOL)] | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-03-10 | — | — | WO | claimed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |